Clinical Trials Browser

INDUSTRY × Diabetes Mellitus, Type 2 × Clear all

ACTH Syndrome, Ectopic, Cushing Syndrome, Diabetes Mellitus, Type 2

NCT03604198 2026-04-21

Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

ACTH Syndrome, Ectopic, Adrenal Cortex Neoplasms, Cushing Syndrome, Diabetes Mellitus, Type 2, Hypertension, Adrenocortical Carcinoma, Pituitary ACTH Hypersecretion

NCT06709040 2026-04-06

A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical Parameters

Enrolling by invitation

500 enrolled

Endocrine

Diabetes Mellitus, Type 2, Dwarfism, Pituitary, Neoplasms

NCT04308590 2025-09-04

GRADIENT

Phase 3 Completed

137 enrolled 25 charts

ACTH Syndrome, Ectopic, Cushing Syndrome, Diabetes Mellitus, Type 2, Hypertension

NCT03697109 2025-07-16

GRACE

Phase 3 Completed

152 enrolled 28 charts

Endocrine

ACTH Syndrome, Ectopic, Cushing Syndrome, Diabetes Mellitus, Type 2, Hypertension, Pituitary ACTH Hypersecretion

NCT07033585 2025-07-11

GD-T2D

Phase 2/3 Active not recruiting

600 enrolled

Diabetes Mellitus, Diabetes Mellitus, Type 2

NCT06976073 2025-05-16

Spectrum1

Recruiting

8,000 enrolled

Dermatologic

Diabetes Mellitus, Type 2, Skin Neoplasms, Diabetic Foot, Peripheral Arterial Disease

NCT03464045 2025-04-20

Empa PASS on Urinary Tract Malignancies

Completed

344,995 enrolled 12 charts

Diabetes Mellitus, Type 2

NCT04373265 2024-02-23

Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)

Phase 1 Completed

15 enrolled

Endocrine

ACTH Syndrome, Ectopic, Adrenal Cortex Neoplasms, Adrenal Gland Diseases, Adrenocortical Hyperfunction, Cushing Syndrome, Diabetes Mellitus, Type 2, Endocrine System Diseases, Hyperglycemia, Hypertension, Pathologic Processes, Glucose Intolerance, Adrenocortical Carcinoma

NCT04572165 2024-01-02

Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data

Unknown

600,000 enrolled

Diabetes Mellitus, Type 2

NCT01511393 2023-06-13

An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)

Enrolling by invitation

6,750 enrolled

Diabetes Mellitus, Diabetes Mellitus, Type 2, Carcinoma, Medullary

NCT02804750 2019-10-15

Study to Evaluate CORT125134 in Participants With Cushing's Syndrome

Phase 2 Completed

35 enrolled 13 charts

Endocrine

ACTH Syndrome, Ectopic, Adrenal Cortex Neoplasms, Cushing Syndrome, Diabetes Mellitus, Type 2, Hypertension, Adrenocortical Carcinoma, Pituitary ACTH Hypersecretion

NCT02608853 2015-11-20

Estimation of Malignancy Rates Within Humedica Patient Populations Sampled to be Representative of Liraglutide Initiators and LEADER™ Trial Participants

Completed

9,999 enrolled

Diabetes Mellitus, Diabetes Mellitus, Type 2

NCT01195259 2013-10-28

Malignancy Meta Analysis for BRL49653

Completed

1 enrolled

Diabetes Mellitus, Type 2, Neoplasms

Clinical Trials

CAPTAIN-T2D

Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical Parameters

GRADIENT

GRACE

GD-T2D

Spectrum1

Empa PASS on Urinary Tract Malignancies

Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)

Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data

An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)

Study to Evaluate CORT125134 in Participants With Cushing's Syndrome

Estimation of Malignancy Rates Within Humedica Patient Populations Sampled to be Representative of Liraglutide Initiators and LEADER™ Trial Participants

Malignancy Meta Analysis for BRL49653